Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Lung Neoplasms 4Breast Neoplasms 3Thyroid Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Carcinoma, Renal Cell 2Carcinoma, Medullary 2Thyroid cancer, medullary 1Thyroid Diseases 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Prostatic Neoplasms 1Pleural Effusion 1Peritoneal Neoplasms 1Neuroblastoma 1Mesothelioma 1Kidney Neoplasms 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Adenocarcinoma, Follicular 1Adenocarcinoma Of Esophagus 1

Interventions

lenvatinib 2Sorafenib 2vandetanib 1tremelimumab 1tovorafenib 1durvalumab 1cabozantinib 1alectinib 1Thyroid (USP) 1Radiofrequency Ablation 1Magnetic Resonance Spectroscopy 1Imatinib Mesylate 1Fluorodeoxyglucose F18 1Ethanol 1Administration, Cutaneous 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Thyroid Cancer, Papillary × vandetanib × Clear all
NCT03630120 2021-07-14

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
6 enrolled 9 charts
EndocrineHead & Neck

Thyroid cancer, medullary, Thyroid Cancer, Papillary, Thyroid Diseases, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡